HACKENSACK MERIDIAN HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2016-01-01

Employees: -

Market Cap: -

Website: https://www.hackensackmeridianhealth.org/

Clinical Trials

Evaluation of the Effects of Ketorolac Dose on Duration of Analgesia in Emergency Department (ED) Renal Colic Patients

Phase 4

Recruiting

Conditions: Flank Pain
Emergencies
Analgesia
Renal Colic

Interventions: Drug: Ketorolac

First Posted Date: 2023-03-20

Last Posted Date: 2024-05-20

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 86

Registration Number: NCT05776953

Locations: 🇺🇸
Hackensack Univarsity medical Center, Hackensack, New Jersey, United States

Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma

Phase 2

Recruiting

Conditions: Osteogenic Sarcoma Recurrent

Interventions: Drug: Iscador*P

First Posted Date: 2023-02-13

Last Posted Date: 2024-11-14

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 32

Registration Number: NCT05726383

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
M.D. Anderson Children's Cancer Hospital, Houston, Texas, United States

Music Therapy Advocacy Recording Intervention (MTAR) on Internalized Stigma

Not Applicable

Terminated

Conditions: Anxiety Disorder
Bipolar Disorder
Mental Health Issues
Depressive
Schizophrenia Spectrum and Other Psychotic Disorders

Interventions: Behavioral: Group Music Therapy Advocacy Recording Intervention (MTAR)

First Posted Date: 2023-02-10

Last Posted Date: 2024-07-05

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 7

Registration Number: NCT05723328

Locations: 🇺🇸
Carrier Clinic, Belle Mead, New Jersey, United States

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Phase 2

Recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Nivolumab
Drug: Ipilimumab
Drug: Carboplatin
Drug: Paclitaxel
Drug: Pemetrexed

First Posted Date: 2023-02-06

Last Posted Date: 2024-01-16

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 108

Registration Number: NCT05715229

Locations: 🇺🇸
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States

Arrythmia Burden in Cardiac Contractility Modulation (CCM)

Terminated

Conditions: Atrial Fibrillation
Arrythmia

Interventions: Device: Impulse Dynamics Optimizer Device

First Posted Date: 2023-01-30

Last Posted Date: 2024-08-19

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 2

Registration Number: NCT05704426

Locations: 🇺🇸
Hackensack Univeristy Medical Center, Hackensack, New Jersey, United States

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

Early Phase 1

Recruiting

Conditions: Urinary Retention

Interventions: Drug: Tamsulosin

First Posted Date: 2022-12-20

Last Posted Date: 2024-10-31

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 46

Registration Number: NCT05657990

Locations: 🇺🇸
Ocean University Medical Center, Brick, New Jersey, United States
🇺🇸
South Ocean University Medical Center, Manahawkin, New Jersey, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States

and more 1 locations

Cardiac Rehabilitation of Stroke Survivors (SRP-CROSS)

Not Applicable

Recruiting

Conditions: Stroke
Cerebrovascular Accident

Interventions: Other: Cardiac rehabilitation program

First Posted Date: 2022-12-15

Last Posted Date: 2024-07-09

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 112

Registration Number: NCT05651945

Locations: 🇺🇸
Hackensack Meridian Health - JFK Johnson Rehabilitation Institute, Edison, New Jersey, United States

Pembrolizumab, Belantamab and Dexamethasone in Refractory Multiple Myeloma.

Phase 1

Withdrawn

Conditions: Multiple Myeloma, Refractory

Interventions: Drug: Pembrolizumab
Drug: Belantamab mafodotin
Drug: Dexamethasone

First Posted Date: 2022-08-09

Last Posted Date: 2023-01-27

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT05493618

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸
Jersey Shore Medical Center, Neptune, New Jersey, United States
🇺🇸
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Iberdomide
Drug: Oral Dexamethasone

First Posted Date: 2022-01-20

Last Posted Date: 2024-08-22

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 66

Registration Number: NCT05199311

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States

Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers

Phase 1

Terminated

Conditions: COVID-19

Interventions: Drug: Omega-3 (EPA+DHA)
Drug: Placebo

First Posted Date: 2021-11-16

Last Posted Date: 2024-03-12

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 32

Registration Number: NCT05121766

Locations: 🇺🇸
Susan Dara, Edison, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy